(Q40999048)

25 September 2017

A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation (English)

1 reference

25 September 2017

Shield CF 3rd

1

1 reference

25 September 2017

Jacobs RJ

series ordinal

2

1 reference

25 September 2017

Wyant S

series ordinal

3

1 reference

25 September 2017

Das A

series ordinal

4

1 reference

25 September 2017

1 June 1996

1 reference

American Journal of Kidney Diseases

25 September 2017

1 reference

25 September 2017

27

1 reference

25 September 2017

6

1 reference

25 September 2017

855-864

1 reference

The Medicare end-stage renal disease program. A report from the Institute of Medicine.

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The quality of life of patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The quality of life of hemodialysis and transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Predicting Treatment Costs and Life Expectancy for End-Stage Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Effect of transplantation on the Medicare end-stage renal disease program

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Cost-effectiveness analysis of transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The effects of intraoperative administration of OKT3 during renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation--a single-center, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

A randomized clinical trial of induction therapy with OKT3 in kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Cost-effective care of end-stage renal disease: a billion dollar question

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The distinction between cost and charges

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

1 reference

7 January 2021

EDF Statistics for Goodness of Fit and Some Comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

The impact of an acute rejection episode on long-term renal allograft survival (t1/2)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990524-7

7 January 2021

10.1016/S0272-6386(96)90524-7

Identifiers

DOI

1 reference

25 September 2017

1 reference